CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

Wenyi Lu(Tianjin First Center Hospital), Mingfeng Zhao(Nankai University), Hairong Lyu(University of Bristol), Haibo Zhu(Tianjin First Center Hospital), Xin Li(Heilongjiang Vocational Institute of Ecological Engineering), Huan Zhang(First Affiliated Hospital of Chongqing Medical University), Qing Li(Nankai University), Xia Xiao(Hebei Medical University), Xiaoyuan He(Nankai University), Kaiqi Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Rui Sun(Nankai University), Yaqing Cao(Tianjin Medical University), Yanyu Jiang(Nankai University), Yili Jiang(Nankai University), Tao Sui(Tianjin First Center Hospital), Yunxiong Wei(Tianjin First Center Hospital), Ting Yuan(China Pharmaceutical University), Juanxia Meng(Nankai University), Xin Jin(Nankai University)
Cancer Immunology Immunotherapy
April 25, 2021
Cited by 22


Related Papers